Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.58 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.47 |
| ▸ | HTR3A | P46098 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | SORD | Q00796 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6887757 | 0.84 | HRH3 (0.58) | HRH3HRH4HTR3AHTTNPC1 | |
| SCHEMBL29292569 | 0.81 | CYP1A2 (0.47) | HRH3HRH4HTR3AKDM4EGAA | |
| SCHEMBL21154005 | 0.79 | CNR2 (0.48) | HRH4HTR3ANPC1RAB9AKDM4E | |
| SCHEMBL30818866 | 0.75 | HTT (0.49) | HRH3HTTNPC1RAB9AKDM4E | |
| SCHEMBL5909974 | 0.75 | HRH3 (0.65) | HRH3HRH4HTR3AKDM4EGAA | |
| SCHEMBL3970431 | 0.74 | HRH3 (1.00) | HRH3HRH4HTR3AHTTNPC1 | |
| SCHEMBL6888105 | 0.74 | HRH3 (0.46) | HRH3HTR3ANPC1RAB9AKDM4E | |
| SCHEMBL25258149 | 0.73 | MAP4K4 (0.58) | MAPT | |
| SCHEMBL4215600 | 0.73 | HRH3 (0.67) | HRH3HRH4HTR3AHTTKDM4E | |
| SCHEMBL23205710 | 0.73 | HRH3 (0.62) | HRH3HRH4HTR3ARAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2501231-B1 | QUINOLIZIDINONE CARBOXAMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2016-12-21 | — | — | EP | disclosed |
| US-8754220-B2 | Quinolizidinone carboxamide M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2014-06-17 | — | — | US | disclosed |
| US-8754220-B2 | Quinolizidinone carboxamide M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2014-06-17 | — | — | US | disclosed |
| US-20120232076-A1 | QUINOLIZIDINONE CARBOXAMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2012-09-13 | — | — | US | disclosed |
| US-20120232076-A1 | QUINOLIZIDINONE CARBOXAMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2012-09-13 | — | — | US | disclosed |
| WO-2011062853-A1 | QUINOLIZIDINONE CARBOXAMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232076-A1 | QUINOLIZIDINONE CARBOXAMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, CHRM2, CHRM4 | HRH3 112/4885HRH4 94/4885HTR3A 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.